Breaking News

Ampio Pharma to Study Ampion in COVID-19 Induced ARDS

Englewood pharmaceutical company looking to treat COVID-19 patients with anti-inflammatory drug

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company focused on the development of immunology based therapies, was featured on a FOX segment titled, “Englewood pharmaceutical company looking to treat COVID-19 patients with anti-inflammatory drug,” reported by an affiliated television station in Denver, Colorado. The primary cause of death associated with SARS-Cov-2 (COVID-19) infection is Acute Respiratory Distress Syndrome (ARDS), and there are no approved trea...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters